15th May 2015 07:56
LONDON (Alliance News) - Pharmaceutical company Oxford Pharmascience Group PLC on Friday said it has completed the development of a chewable ibuprofen product.
The chewable version of its OXPzero ibuprofen product will reduce the risk of gastric irritation and will also mask the taste of the ibuprofen.
"The development and progression of a chewable taste-masked ibuprofen tablet to the clinic will not only provide the data to further confirm the GI irritation reduction benefit of the OXPzero technology but will also provide evidence in a clinical setting of its taste-masking ability," said Chief Executive Marcelo Bravo.
Oxford Pharmascience shares were up 13% to 10.45 pence on Friday, one of the best performers in the AIM All-Share.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group